- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02201654
Stylet vs No Stylet During EBUS TBNA
Stylet Versus no Stylet in Endobronchial Ultrasound Transbronchial Aspiration (EBUS-TBNA)
This research study compares two ways to biopsy lymph nodes in the chest using endobronchial ultrasound-guided transbronchial needle aspiration" (EBUS-TNBA). During a EBUS-TBNA procedure, the patient is sedated, and a flexible camera and ultrasound probe is inserted through the mouth into the large airways of the chest, allowing us to see (via ultrasound) and biopsy the lymph nodes in the chest.
The purpose of this research study is to determine if the EBUS-TBNA procedure can be made simpler. In today's practice, the biopsy needle has two parts, 1) the needle itself and 2) an inner stylet that runs through the middle of the needle. Because many other biopsy needles (such as the needles used in breast biopsy and different types of lung biopsy needles) do not use an inner stylet, the investigators do not think the use of a stylet is necessary. If this step can be safely eliminated without decreasing the effectiveness of the procedure, this could shorten the procedure (saving time). This study is deigned to formally test the hypothesis that a stylet is not necessary in EBUS-TBNA.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21218
- Johns Hopkins Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All patients >18 years old and capable of informed consent refereed for EBUS-TBNA at our institution.
Exclusion Criteria:
- Standard contraindications to EBUS (coagulopathy, anti-platlet/anti-coagulant use, clinical instability)
- Pregnant women
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: EBUS patients
All patients in our study are in the same arm, as each patient serves as their own internal control.
More specifically, each enrolled patient will receive both traditional EBUS (with the usage of stylet) and experimental EBUS (EBUS without a stylet) at each lymph node that is included in the experimental analysis.
|
the patient will receive both conventional ebus with the stylet and experimental ebus (without the stylet).
The two techniques will then be compared to each other on a per lymph node basis.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Diagnostic agreement (percentage of samples that have the same diagnosis)
Time Frame: At time of biopsy
|
The main outcome is the agreement (concordance) between the pathological diagnosis obtained by preforming EBUS with a stylet with EBUS without a stylet.
Each patient will receive both techniques on each lymph node.
We will then compare the diagnostic reached by each technique, and calculate the percentage of the time these techniques result in the same diagnosis.
|
At time of biopsy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pneumothorax rate (percentage of procedures that result in a pneumothorax)
Time Frame: 1 week post-procedure
|
Complications related to EBUS-TBNA are very rare, and are not anticipated to be higher due to enrollment in this study.
We will track complications such as excessive bleeding, pneumothorax, and unanticipated admission to the hospital
|
1 week post-procedure
|
|
Bleeding rate (% of procedures that have significant bleeding)
Time Frame: 1 week post-procedure
|
Complications related to EBUS-TBNA are very rare, and are not anticipated to be higher due to enrollment in this study.
We will track complications such as excessive bleeding, pneumothorax, and unanticipated admission to the hospital
|
1 week post-procedure
|
|
Hospital Admission (% of procedures that result in unanticipated admission to the hospital)
Time Frame: 1 week post-procedure
|
Complications related to EBUS-TBNA are very rare, and are not anticipated to be higher due to enrollment in this study.
We will track complications such as excessive bleeding, pneumothorax, and unanticipated admission to the hospital
|
1 week post-procedure
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NA_00093452
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Interstitial Lung Disease
-
Matthias GrieseTerminatedInterstitial Lung Disease | Diffuse Parenchymal Lung Disease | Children´s Interstitial Lung DiseaseGermany
-
Nuwacell Biotechnologies Co., Ltd.Not yet recruiting
-
Boehringer IngelheimNo longer availableLung Diseases, Interstitial (in Pediatric Populations) | Childhood Interstitial Lung Disease (chILD)
-
St. Lawrence Health SystemNot yet recruitingInterstitial Lung Disease Due to Systemic Disease | Interstitial Lung Disease Due to Systemic Disease (Disorder) | Interstitial Lung Disease in Patients With Rheumatoid ArthritisUnited States
-
University of AarhusAarhus University HospitalActive, not recruitingProgressive Fibrosing Interstitial Lung DiseaseDenmark
-
West Virginia UniversityWithdrawnProgressive Fibrosing Interstitial Lung DiseaseUnited States
-
Dai HuapingTongji Hospital; Shanghai Chest Hospital; The First Affiliated Hospital of Guangzhou... and other collaboratorsRecruitingInterstitial Lung Disease (ILD)China
-
University of AlbertaAlberta Boehringer Ingelheim CollaborationRecruitingFibrotic Interstitial Lung DiseaseCanada
-
Monash UniversityCompletedFibrotic Interstitial Lung DiseaseAustralia
-
Heidelberg UniversityHelmholtz Zentrum München; University of Giessen; Lungenfibrose e.V.; German Center... and other collaboratorsCompletedInterstitial Lung Disease (ILD)Germany
Clinical Trials on EBUS without stylet
-
All India Institute of Medical Sciences, New DelhiUnknown
-
American Society for Gastrointestinal EndoscopyMidwest Biomedical Research FoundationUnknownMediastinal or Intra-abdominal Lymphadenopathy, | Pancreatic Masses, | Left Adrenal Masses, | Gastrointestinal Submucosal Lesions, and | Liver MassesUnited States
-
American University of Beirut Medical CenterCompleted
-
Samsung Medical CenterCompletedPancreatic Neoplasm | Neoplasm of Intra-abdominal Lymph NodesKorea, Republic of
-
Washington University School of MedicineCompletedBiopsy, Fine-Needle | Endosonography | Biopsy, Fine-Needle/MethodsUnited States
-
Lawson Health Research InstituteUnity Health Toronto; London Health Sciences CentreCompleted
-
Medtronic EndovascularTerminatedVenous InsufficiencyUnited States
-
The University of Texas Health Science Center at...Withdrawn
-
Diskapi Teaching and Research HospitalCompletedDifficult IntubationTurkey
-
Damanhour Teaching HospitalCompletedOrotracheal IntubationEgypt